MAPROTILINE HYDROCHLORIDE

MAPROTILINE HYDROCHLORIDE
(ma-proe'ti-leen)
Maprotiline HCl
Classifications: psychotherapeutic; tetracyclic antidepressant;
Therapeutic: antidepressant

Prototype: Mirtazapine
Pregnancy Category: B

Availability

25 mg, 50 mg, 75 mg tablets

Action

It selectively inhibits reuptake of norepinephrine at the neuronal membrane. More recent evidence suggests that a better explanation than norepinephrine reuptake may be that the upset of monoamine output (MAO) present in depressed individuals may be regulated by the action of beta-adrenergic receptors following long-term use of these drugs.

Therapeutic Effect

Useful in depression associated with anxiety and sleep disturbances.

Uses

Treatment of depressive neurosis (dysthymic disorder) and manic-depressive illness, depressed type (major depressive disorder).

Unlabeled Uses

Bulimia, pain, panic attack.

Contraindications

Acute MI, AV block, cardiac arrhythmias, QT prolongation; MAOI therapy; tricyclic antidepressant therapy; patients <18 y; history of alcoholism; suicidal ideation; lactation.

Cautious Use

History of seizure activity; psychotic disorders; diabetes mellitus; hepatic disease; GI disease; GERD; BPH; respiratory depression; pregnancy (category B).

Route & Dosage

Mild to Moderate Depression
Adult: PO Start at 75 mg/d and gradually increase q2wk up to 150 mg/d in single or divided doses
Geriatric: PO Start with 25 mg h.s. and gradually increase to 50–75 mg/d

Severe Depression
Adult: PO Start at 100–150 mg/d and gradually increase up to 300 mg/d in single or divided doses if needed

Administration

Oral
  • Give as single dose or in divided doses. Initiate therapy with low dosages to reduce risk of seizures.
  • Store at 15°–30° C (59°–86° F) unless otherwise specified.

Adverse Effects (≥1%)

CNS: Seizures, exacerbation of psychosis, hallucinations, tremors, excitement, confusion, dizziness, drowsiness. CV: Orthostatic hypotension, hypertension, tachycardia. Special Senses: Accommodation disturbances, blurred vision, mydriasis. GI: Nausea, vomiting, epigastric distress, constipation, dry mouth. Urogenital: Urinary retention, frequency. Skin: Hypersensitivity reactions (skin rash, urticaria, photosensitivity).

Interactions

Drug: May decrease some response to antihypertensives; cns depressants, alcohol, hypnotics, barbiturates, sedatives potentiate CNS depression; may increase hypoprothrombinemic effect of oral anticoagulants; transient delirium with ethchlorvynol; with levodopa, sympathomimetics (e.g., epinephrine, norepinephrine) there is possibility of sympathetic hyperactivity with hypertension and hyperpyrexia; with mao inhibitors or linezolid there is possibility of severe reactions, toxic psychosis, cardiovascular instability; methylphenidate increases plasma TCA levels; thyroid drugs increase possibility of arrhythmias; cimetidine may increase plasma TCA levels.

Pharmacokinetics

Absorption: Slowly absorbed from GI tract. Peak: 12 h. Distribution: Distributed chiefly to brain, lungs, liver, and kidneys. Metabolism: In liver. Elimination: 70% in urine, 30% in feces. Half-Life: 51 h.

Nursing Implications

Assessment & Drug Effects

  • Monitor for therapeutic effectiveness; 2–3 wk are usually necessary for full effect.
  • Monitor for increased suicidality, unusual changes in behavior, or suicide attempt. Inform the physician immediately.
  • Assess level of sedative effect. If recovering patient becomes too lethargic to care for personal hygiene or to maintain food intake and interactions with others, report to physician.
  • Monitor bowel elimination pattern and I&O ratio. Severe constipation and urinary retention are potential problems, especially in the older adult. Advise increased fluid intake (at least 1500 mL/d).
  • Observe seizure precautions; risk of seizures appears to be high in heavy drinkers.
  • Bear in mind that if patient uses excessive amounts of alcohol, potentiated effects of maprotiline may increase the danger of overdosage or suicide attempt.

Patient & Family Education

  • Report symptoms of stomatitis and dry mouth when taking high doses. Sore or dry mouth can lead to lack of compliance.
  • Use caution with tasks that require alertness and skill; ability may be impaired during early therapy.
  • Do not change dose or dose schedule without consulting physician.
  • Do not use OTC drugs unless approved by physician.
  • Avoid alcohol; the effects of maprotiline are potentiated when both are used together and for 2 wk after maprotiline is discontinued.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(32)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.
© 2006-2025 medpill.info Last Updated On: 03/10/2025 (0.01)
×
Wait 20 seconds...!!!